Natalie Dean, PhD, Why the Test-Negative Design Is Used for Routine Vaccine Monitoring (2026) is a certified entry in Truverai's communication library, filed as a communication of 1290 words. Its composite score is 93 out of 100.
From the communication: In their new study, Wiegand and colleagues1 report interim estimates of the effectiveness of the 2025-2026 COVID-19 vaccine in immunocompetent adults. Using data from the Centers for Disease Control a
Natalie Dean, PhD's text was scored under the same locked configuration as every other entry in the library, which is what makes the 93 comparable to the rest. Truverai measures how a communication is presented, not whether the speaker was right, and it scores what was said rather than who said it.
This page needs JavaScript for the full interactive view. The summary above is the same information in plain HTML.